NL-OMON31130已完成不适用
Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study - MARRS
MitralSolutions, Inc.0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Males or females aged *18 to *75 years. ;Patients with *Grade 2+ mitral regurgitation by pre-operative Trans-Thoracic Echo assessment.;Candidate for cardiopulmonary bypass. ;A Left Ventricular Ejection Fraction *40%. ;Able and willing to comply with all study requirements, including the required study follow-up visits. ;Able and willing to give consent and follow study instructions. ;Female patients of childbearing potential (not surgically sterilized or more than one year postmenopausal), with a negative pregnancy test (serum beta-hCG) within 24 hours prior to mitral valve surgery.
排除标准
- •Any previous cardiac surgery.;Any interventional cardiology procedure within six months prior to study to include all patients that have had a drug eluting stent (DES) implanted within 6 months. ;Evidence of an acute Myocardial Infarction (MI) within 7 days of the intended treatment with the investigational device.;Prior mitral valve surgery or valvuloplasty or currently implanted prosthetic valve.
- •Restricted mobility of the mitral apparatus that results in a valvular area less than 3.0 cm2.;Recent or evolving bacterial endocarditis or patients under current antibiotic therapy.;Patients with ICD*s.;Any angiographic or clinical evidence that the investigator feels would place the patient at increased risk with the placement of the device or concurrent medical condition with a life expectancy of less than 12 months.;Patients who are immunocompromised or with autoimmune diseases.;Patients suffering from renal insufficiency (Creatinine >2.5 mg/dL) or patients with chronic renal failure undergoing dialysis.;Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. sever chronic obstructive pulmonary disease, hepatic failure, immunosuppressive abnormalities, haematological abnormalities).;Significant mitral annular calcification.;Use of Coumadin, IIbIIIa inhibitors, Clopidigrel (Plavix) or other anti-coagulants within (5) five days prior to surgery. ;Participation in any study involving an investigational drug or device within the past month, or ongoing participation in a study with an investigational device.
- •Intolerance or hypersensitivity to anaesthetics.;Patients in whom transesophageal echo/Doppler is contraindicated.;History of bleeding diathesis or coagulopathy.;History of stroke within the prior 6 months.;Subjects to undergo concomitant cardiac surgical repair or replacement other than CABG (3 vessels or less) and mitral annuloplasty. Excluded concomitant procedures are: aortic valve replacement, tricuspid repair or replacement, left ventricular remodelling surgery and congenital repair.;Patients with a Euroscore >10.
研究者
相似试验
已完成
不适用
Mitral Adjustable Annuloplasty Ring Feasibility and Safety StudyMitral Valve RegurgitationNCT00554151Abbott Medical Devices55
招募中
不适用
Retrospective observation of mitral valve repair in adultsKCT0006408Koera University Guro Hospital23
已完成
不适用
Mitral valve surgery using stentress bioprosthesis made from autologous pericardiumMitral insufficiencyJPRN-UMIN000017201CV suregry5
已完成
不适用
Is Mitral Annuloplasty an Effective Treatment for Severe Atrial Functional MR?Mitral RegurgitationNCT05836376Michele De Bonis55
已完成
不适用
Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitatiomitral valve regurgitation10046973NL-OMON46895Valtech Cardio LTD10